"Fluvoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
Descriptor ID |
D016666
|
MeSH Number(s) |
D02.092.570.665.250
|
Concept/Terms |
Luvox- Luvox
- Floxyfral
- Fevarin
- Dumirox
- Faverin
|
Below are MeSH descriptors whose meaning is more general than "Fluvoxamine".
Below are MeSH descriptors whose meaning is more specific than "Fluvoxamine".
This graph shows the total number of publications written about "Fluvoxamine" by people in this website by year, and whether "Fluvoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2022 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluvoxamine" by people in Profiles.
-
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin Infect Dis. 2024 Aug 16; 79(2):354-363.
-
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023 10; 23(10):1119-1129.
-
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 08 18; 387(7):599-610.
-
Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud. 2005; 21(4):431-43.
-
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep; 32(9):930-6.
-
Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998 Dec; 155(12):1756-62.